

# Heidi Schwarzenbach

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1989205/publications.pdf>

Version: 2024-02-01

82  
papers

8,763  
citations

81839

39  
h-index

66879

78  
g-index

84  
all docs

84  
docs citations

84  
times ranked

13485  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Cell-free nucleic acids as biomarkers in cancer patients. <i>Nature Reviews Cancer</i> , 2011, 11, 426-437.  | 12.8 | 2,372     |
| 2  | Clinical relevance of circulating cell-free microRNAs in cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 145-156.  | 12.5 | 915       |
| 3  | Circulating Tumor Cells and Circulating Tumor DNA. <i>Annual Review of Medicine</i> , 2012, 63, 199-215.   | 5.0  | 411       |
| 4  | Data Normalization Strategies for MicroRNA Quantification. <i>Clinical Chemistry</i> , 2015, 61, 1333-1342.  | 1.5  | 384       |
| 5  | Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. <i>Breast Cancer Research</i> , 2010, 12, R90.  | 2.2  | 374       |
| 6  | Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. <i>Oncotarget</i> , 2014, 5, 9650-9663.   | 0.8  | 304       |
| 7  | Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone Metastasis. <i>Cancer Cell</i> , 2013, 24, 542-556.   | 7.7  | 251       |
| 8  | Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1032-1038.   | 3.2  | 221       |
| 9  | Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 16923-16935.   | 0.8  | 207       |
| 10 | Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression. <i>Clinical Chemistry</i> , 2013, 59, 1489-1496.   | 1.5  | 180       |
| 11 | Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells. <i>Molecular Cancer Research</i> , 2006, 4, 339-349.  | 1.5  | 163       |
| 12 | Detection and Monitoring of Cell-Free DNA in Blood of Patients with Colorectal Cancer. <i>Annals of the New York Academy of Sciences</i> , 2008, 1137, 190-196.  | 1.8  | 158       |
| 13 | Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 933-941.   | 1.1  | 148       |
| 14 | Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. <i>BMC Medicine</i> , 2018, 16, 179.  | 2.3  | 134       |
| 15 | Exosomal microRNA as tumor markers in epithelial ovarian cancer. <i>Molecular Oncology</i> , 2018, 12, 1935-1948.  | 2.1  | 125       |
| 16 | Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. <i>British Journal of Cancer</i> , 2015, 113, 1358-1366.   | 2.9  | 110       |
| 17 | Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 61-68. | 1.1  | 108       |
| 18 | Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. <i>BJU International</i> , 2006, 98, 544-548.   | 1.3  | 104       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. <i>Molecular Oncology</i> , 2011, 5, 281-291.  | 2.1 | 97        |
| 20 | Circulating nucleic acids as biomarkers in breast cancer. <i>Breast Cancer Research</i> , 2013, 15, 211.  | 2.2 | 95        |
| 21 | Circulating DNA as biomarker in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 136.   | 2.2 | 89        |
| 22 | Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. <i>Oncotarget</i> , 2015, 6, 13387-13401.                               | 0.8 | 88        |
| 23 | Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer. <i>Molecular Oncology</i> , 2019, 13, 1137-1149.   | 2.1 | 84        |
| 24 | Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. <i>BMC Cancer</i> , 2011, 11, 4.   | 1.1 | 81        |
| 25 | The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1159-1169.   | 1.5 | 77        |
| 26 | MicroRNA Shuttle from Cell-To-Cell by Exosomes and Its Impact in Cancer. <i>Non-coding RNA</i> , 2019, 5, 28.   | 1.3 | 77        |
| 27 | Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. <i>International Journal of Cancer</i> , 2011, 128, 2572-2580. | 2.3 | 71        |
| 28 | Low Levels of Cell-Free Circulating miR-361-3p and miR-625* as Blood-Based Markers for Discriminating Malignant from Benign Lung Tumors. <i>PLoS ONE</i> , 2012, 7, e38248.   | 1.1 | 66        |
| 29 | Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression. <i>Clinical Cancer Research</i> , 2012, 18, 5719-5730.                                 | 3.2 | 63        |
| 30 | Implementing liquid biopsies into clinical decision making for cancer immunotherapy. <i>Oncotarget</i> , 2017, 8, 48507-48520.  | 0.8 | 63        |
| 31 | Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. <i>Molecular BioSystems</i> , 2011, 7, 2848.   | 2.9 | 61        |
| 32 | Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients. <i>Scientific Reports</i> , 2018, 8, 12974.  | 1.6 | 59        |
| 33 | Detection and Characterization of Circulating Microsatellite-DNA in Blood of Patients with Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2004, 1022, 25-32.  | 1.8 | 54        |
| 34 | Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. <i>International Journal of Cancer</i> , 2007, 120, 1465-1471.  | 2.3 | 54        |
| 35 | Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. <i>Breast Cancer Research</i> , 2009, 11, R71.   | 2.2 | 53        |
| 36 | Clinical Relevance of Circulating, Cell-Free and Exosomal microRNAs in Plasma and Serum of Breast Cancer Patients. <i>Oncology Research and Treatment</i> , 2017, 40, 423-429.  | 0.8 | 52        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Circulating Mitochondrial DNA as Biomarker Linking Environmental Chemical Exposure to Early Preclinical Lesions Elevation of mtDNA in Human Serum after Exposure to Carcinogenic Halo-Alkane-Based Pesticides. <i>PLoS ONE</i> , 2013, 8, e64413.   | 1.1 | 49        |
| 38 | Methyl-CpG Binding Domain Proteins and Their Involvement in the Regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 Gene Promoters. <i>Molecular Cancer Research</i> , 2007, 5, 749-759.  | 1.5 | 40        |
| 39 | Identification of Loss of Heterozygosity on Circulating Free DNA in Peripheral Blood of Prostate Cancer Patients: Potential and Technical Improvements. <i>Clinical Chemistry</i> , 2008, 54, 688-696.  | 1.5 | 40        |
| 40 | Plasma microRNA signature is associated with risk stratification in prostate cancer patients. <i>International Journal of Cancer</i> , 2017, 141, 1231-1239.  | 2.3 | 40        |
| 41 | Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. <i>BJU International</i> , 2008, 102, 253-258.   | 1.3 | 38        |
| 42 | Comparison of Genetic Alterations Detected in Circulating Microsatellite DNA in Blood Plasma Samples of Patients with Prostate Cancer and Benign Prostatic Hyperplasia. <i>Annals of the New York Academy of Sciences</i> , 2006, 1075, 222-229.  | 1.8 | 37        |
| 43 | LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival. <i>BMC Cancer</i> , 2012, 12, 325.   | 1.1 | 37        |
| 44 | Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 924, 3-8.   | 0.8 | 37        |
| 45 | Diagnosis, monitoring and prevention of exposure-related non-communicable diseases in the living and working environment: DiMoPEX-project is designed to determine the impacts of environmental exposure on human health. <i>Journal of Occupational Medicine and Toxicology</i> , 2018, 13, 6. | 0.9 | 32        |
| 46 | Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by Methyl-CpG binding proteins and histone modifications. <i>BMC Cancer</i> , 2010, 10, 297.  | 1.1 | 31        |
| 47 | MicroRNA expression studies: challenge of selecting reliable reference controls for data normalization. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3497-3514.  | 2.4 | 29        |
| 48 | Potential microRNA-related targets in clearance pathways of amyloid- $\beta$ : novel therapeutic approach for the treatment of Alzheimer's disease. <i>Cell and Bioscience</i> , 2019, 9, 91.   | 2.1 | 29        |
| 49 | Biological and Clinical Relevance of H19 in Colorectal Cancer Patients. <i>EBioMedicine</i> , 2016, 13, 9-10.   | 2.7 | 28        |
| 50 | Circulating Mitochondrial DNA is Linked to Progression and Prognosis of Epithelial Ovarian Cancer. <i>Translational Oncology</i> , 2019, 12, 1213-1220.   | 1.7 | 28        |
| 51 | A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer. <i>Breast Cancer Research</i> , 2007, 9, R66.   | 2.2 | 26        |
| 52 | Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 811-819.  | 1.2 | 25        |
| 53 | Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. <i>Oncotarget</i> , 2017, 8, 56398-56407.  | 0.8 | 25        |
| 54 | Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients. <i>Cancers</i> , 2021, 13, 2484.   | 1.7 | 23        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Exosomes in Immune Regulation. Non-coding RNA, 2021, 7, 4.   | 1.3 | 23        |
| 56 | The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder. World Journal of Urology, 2019, 37, 1785-1799.   | 1.2 | 18        |
| 57 | Monitoring of Loss of Heterozygosity in Serum Microsatellite DNA Among Patients with Gastrointestinal Stromal Tumors Indicates Tumor Recurrence. Journal of Surgical Research, 2011, 169, 31-35.   | 0.8 | 17        |
| 58 | Characterization of circulating DNA in plasma of patients after allogeneic bone grafting. Clinical Oral Investigations, 2019, 23, 4243-4253.   | 1.4 | 15        |
| 59 | Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein. BMC Cancer, 2014, 14, 796.  | 1.1 | 14        |
| 60 | Impact of Physical Activity and Doping on Epigenetic Gene Regulation. Drug Testing and Analysis, 2011, 3, 682-687.   | 1.6 | 12        |
| 61 | The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response. Expert Review of Molecular Diagnostics, 2015, 15, 267-275.  | 1.5 | 12        |
| 62 | The current role of circulating biomarkers in non-muscle invasive bladder cancer. Translational Andrology and Urology, 2019, 8, 61-75.   | 0.6 | 11        |
| 63 | Molecular analysis of the polymorphisms of thymidylate synthase on cell-free circulating DNA in blood of patients with advanced colorectal carcinoma. International Journal of Cancer, 2010, 127, 881-888.   | 2.3 | 10        |
| 64 | A novel assay for exosomal and cell-free miRNA isolation and quantification. RNA Biology, 2020, 17, 425-440.   | 1.5 | 10        |
| 65 | Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients. , 2019, 2, 271-296.   |     | 9         |
| 66 | Clinical significance of miR-15 and miR-16 in ovarian cancer. Translational Cancer Research, 2016, 5, S50-S53.   | 0.4 | 9         |
| 67 | Loss of heterozygosity proximal to the <i>M6P/IGF2R</i> locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy. Genes Chromosomes and Cancer, 2011, 50, 598-605. | 1.5 | 7         |
| 68 | Circulating nucleic acids and protease activities in blood of tumor patients. Expert Opinion on Biological Therapy, 2012, 12, S163-S169.   | 1.4 | 6         |
| 69 | Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy. Scientific Reports, 2020, 10, 21562.  | 1.6 | 6         |
| 70 | Methods for quantification and characterization of microRNAs in cell-free plasma/serum, normal exosomes and tumor-derived exosomes. Translational Cancer Research, 2018, 7, S253-S263.   | 0.4 | 5         |
| 71 | The History and Future of Basic and Translational Cell-Free DNA Research at a Glance. Diagnostics, 2022, 12, 1192.   | 1.3 | 5         |
| 72 | Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy. EPMA Journal, 2010, 1, 485-494.  | 3.3 | 4         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patients. , 2020, 3, 63-82.   |     | 4         |
| 74 | MicroRNAs and their Implications in CD4+ T-cells, Oligodendrocytes and Dendritic Cells in Multiple Sclerosis Pathogenesis. Current Molecular Medicine, 2023, 23, 630-647.   | 0.6 | 4         |
| 75 | Copy Number Variation Analysis on Cell-Free Serum DNA. Methods in Molecular Biology, 2019, 1909, 85-93.   | 0.4 | 3         |
| 76 | Similar patterns of loss of heterozygosity in serum of adenocarcinoma of the distal oesophagus and the cardia in early diagnosis. Anticancer Research, 2007, 27, 477-81.  | 0.5 | 3         |
| 77 | Diagnostic relevance of circulating cell-free and exosomal microRNAs and long non-coding RNAs in blood of cancer patients. Laboratoriums Medizin, 2016, 40, 345-353.  | 0.1 | 2         |
| 78 | Circulating non-coding RNAs in recurrent and metastatic ovarian cancer. , 2019, 2, 399-418.   |     | 2         |
| 79 | Characterization of circulating molecules and activities in plasma of patients after allogeneic and autologous intraoral bone grafting procedures: a prospective randomized controlled clinical trial in humans. BMC Oral Health, 2022, 22, 24. | 0.8 | 2         |
| 80 | Microsatellite Analysis in Serum DNA as a Diagnostic Tool for Distinction of Patients With Unknown Pancreatic Masses. Diagnostic Molecular Pathology, 2007, 16, 174-178.  | 2.1 | 1         |
| 81 | Detection and oncological impact of circulating tumor cells in bladder cancer patients with presence of copy number variations of circulating cell free DNA.. Journal of Clinical Oncology, 2018, 36, 495-495.                                  | 0.8 | 1         |
| 82 | Novel Technology for Enrichment of Biomolecules from Cell-Free Body Fluids and Subsequent DNA Sizing. Advances in Experimental Medicine and Biology, 2016, 924, 165-169.  | 0.8 | 0         |